- WORLD EDITIONAustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
Recro Pharma Acquires Neuromuscular Blocking Agents
Recro Pharma announced the acquisition of exclusive global rights to two novel neuromuscular blocking agents and a proprietary chemical reversal agent from Cornell University.
Recro Pharma (NASDAQ:REPH) announced the acquisition of exclusive global rights to two novel neuromuscular blocking agents and a proprietary chemical reversal agent from Cornell University.
As quoted in the press release:
The assets include one novel intermediate-acting neuromuscular blocking agent that has completed Phase I trials, one short-acting neuromuscular blocking agent, as well as a rapid-acting reversal agent proprietary to these compounds. The novel neuromuscular blocking agents acquired through this agreement permit a very rapid induction of neuromuscular blockade at the onset of use and the novel reversal agent will provide for more rapid reversal of the neuromuscular blockade. These novel agents may meaningfully reduce the patient’s post-procedure time in the operating room or post-acute care unit and could provide valuable cost savings to hospitals and ambulatory surgical centers.
“Cornell University is pleased to have licensed a series of proprietary neuromuscular blocking drugs to Recro Pharma Inc. and we look forward to working with them to commercialize this much needed technology for the benefit of patients and the medical community,” said Dr. Brian Kelly, the Director of Cornell’s Center for Technology Licensing at Cornell University.
Click here to read the full press release.
Source: globenewswire.com
Outlook Reports
Featured Pharmaceutical Investing Stocks
Browse Companies
MARKETS
COMMODITIES
Commodities | |||
---|---|---|---|
Gold | 2174.18 | +5.76 | |
Silver | 24.69 | 0.00 | |
Copper | 4.01 | +0.01 | |
Oil | 81.95 | +1.32 | |
Heating Oil | 2.67 | +0.03 | |
Natural Gas | 1.61 | -0.05 |
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.